The California-based multinational giant Amgen recently finalised an investment of $2.8 billion in Chinese pharmaceuticals, and it seems that the trends of the 2010s will continue as China continues to assert itself as a major player in the global biotechnology and pharmaceutical trades. Amgen itself has aggressively expanded its global influence since 2011, doubling its geographic presence from around 50 …
CSC participated in the 2019 Global DIA (Drug Information Association) Annual Meeting, June 23-June 27, San Diego.
11 Drugs in the First Batch, Released in August 2018, Have Already Obtained Marketing Approval! On 28th March, CDE published a list of “the second batch of overseas new drugs that meet urgent clinical needs (in China)”, there are 30 drugs on the list! There are 17 Rare Diseases in the second batch CDE published the list of overseas new …
On 8th August, 2018 (20180808 – a great number in Chinese), the CNDA (CDE) provided a list of 48 New Drugs that are “urgently needed in China” and that are “already marketed overseas.” These drugs will be offered an expedited evaluation process in accordance with the priority review procedure in a conscious effort to get them to market as soon …
